Monoclonal Antibody to Annexin A5 (ANXA5)
| Code | Size | Price |
|---|
| MAA259Hu22-20ul | 20ul | £85.00 |
Quantity:
| MAA259Hu22-100ul | 100ul | £156.00 |
Quantity:
| MAA259Hu22-200ul | 200ul | £210.00 |
Quantity:
| MAA259Hu22-1ml | 1ml | £480.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
ANX5; ENX2; PP4; PAP-I; CBP-I; Anchorin CII; Calphobindin I; Endonexin II; Lipocortin V; Placental anticoagulant protein 4; Thromboplastin inhibitor; Vascular anticoagulant-alpha
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Annexin V
Potency (Clone Number):
C13
Reactivity:
Gu;Rb;Ca;Po;Bo;Ov;Eq;
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.2-4ug/mL;<br/>Immunohistochemistry: 2-40ug/mL;<br/>Immunocytochemistry: 2-40ug/mL;<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Annexin A5 (ANXA5) | RPA259Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||